Scrip Awards 2020
The 16th Annual Scrip Awards, 2 December 2020, London
Entry Deadline Extended to 22 June.
Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising. In the current climate it’s more important than ever to recognize what has been achieved.
This year, we have introduced a new category – China Biopharma Leadership Award – to reflect the rapid maturing of China’s biopharma sector, thanks to the development of homegrown biopharma companies, CDMOs and increasing investment in the market from global multinational biopharma companies.
Over the past 16 years, the Scrip Awards has carved out a unique place in the industry calendar, with attendees coming from around the world to the prestigious ceremony, which this year will take place in the London Hilton on Park Lane in Mayfair on 2 December.
The entry deadline is 22 June. Now is the time to prepare your entry and make sure you take your place among the best.
The safety and experience of our customers and teams are always our top priority. As such, we’re closely monitoring developments with COVID-19. We are following all government and health authority advice and are working with our venue partners to put in place a number of enhanced safety and hygiene measures at the Scrip Awardsand ensure a good event for everyone. For any questions, please contact our Lisa Anderberg. We will keep this page updated as the situation changes.
We look forward to seeing you at the Scrip Awards for what is always a great chance to build relationships, make new partnerships and celebrate our industry and its latest achievements.
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies.With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,100 employees.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com.
A Legacy of Innovation
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2019 MSD had sales of more than $46 billion and we operate in more than 140 countries.
Partnering With MSD
We recognize that building partnerships is one of our most important jobs. In 2019, over 65% of our human health revenue was attributable to acquisitions, alliance partnerships and patents. With more than 100 significant business development transactions since 2017, we have BD professionals based in key biomedical innovation epicenters including Boston, San Francisco, London, Shanghai, Sydney, Tokyo and our headquarters in Kenilworth, NJ.
We’re pursuing the most innovative areas in biomedical research emerging today without regard to therapeutic area or modality and working on collaborations from discovery to clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can Invent For Life.
Learn more at msd.com/licensing.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that "every drug can be made and every disease can be treated."